You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

ADT

Showing 1 - 25 of 622
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Prostate Cancer Trial in Chicago (Docetaxel, ADT, Abiraterone)

Not yet recruiting
  • Prostate Cancer
  • Chicago, Illinois
    Northwestern University
Sep 27, 2023

Metastatic Prostate Cancer, Hormone Sensitive Prostate Cancer, Chemo Effect Trial in Nanjing (Docetaxel, Rezvilutamide)

Recruiting
  • Metastatic Prostate Cancer
  • +2 more
  • Nanjing, Jiangsu, China
    Urology dpt, First Affiliated Hospital of Nanjing Medical Univer
Aug 2, 2023

Cohort Studies Trial in Jinan (apantamide+docetaxel+ADT, apantamide+ADT treatment)

Recruiting
  • Cohort Studies
  • Jinan, Shandong, China
    Qilu hospital
Feb 3, 2023

Prostate Cancer Trial in Beijing (Darolutamide+ADT)

Not yet recruiting
  • Prostate Cancer
  • Beijing, China
    Peking University First Hospital
Sep 1, 2023

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Trial in Milano, Milan (APA + ADT, Local Treatmetn RT or RP)

Not yet recruiting
  • Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
  • APA + ADT
  • Local Treatmetn RT or RP
  • Milano, Lombardia, Italy
  • +2 more
Jan 17, 2023

Prostatic Tumor, Survivorship, Frailty Trial in Baltimore (Dietary recommendations, Time-restricted eating)

Not yet recruiting
  • Prostatic Neoplasm
  • +3 more
  • Dietary recommendations
  • Time-restricted eating
  • Baltimore, Maryland
    University of Maryland, Baltimore
Jul 21, 2023

Metastatic Prostate Cancer Trial in Toronto (Enzalutamide, Standard of Care SBRT and ADT)

Not yet recruiting
  • Metastatic Prostate Cancer
  • Toronto, Ontario, Canada
    Princess Margaret Cancer Center
Oct 6, 2022

Metastatic Castrate-sensitive Prostate Cancer Trial in Germany, United States (Apalutamide, Androgen-deprivation Therapy (ADT))

Not yet recruiting
  • Metastatic Castrate-sensitive Prostate Cancer
  • Lakewood, Colorado
  • +5 more
May 23, 2023

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Trial (Standard ADT (androgen deprivation therapy), Standard Darolutamide,

Not yet recruiting
  • Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
  • Standard ADT (androgen deprivation therapy)
  • +2 more
  • (no location specified)
Jan 6, 2023

Metastatic Hormone-sensitive Prostate Cancer Trial in United States (Darolutamide (BAY1841788, Nubeqa), ADT)

Recruiting
  • Metastatic Hormone-sensitive Prostate Cancer
  • Darolutamide (BAY1841788, Nubeqa)
  • ADT
  • Homewood, Alabama
  • +11 more
Jan 13, 2023

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Trial in Nanjing (6-month course of antiandrogen drugs, Long-term course of

Recruiting
  • Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
  • 6-month course of antiandrogen drugs
  • Long-term course of antiandrogen drugs
  • Nanjing, Jiangsu, China
    Urology dpt, First Affiliated Hospital of Nanjing Medical Univer
Jul 13, 2023

PROSTATE CANCER, Metastatic Prostate Cancer, Metastatic Prostate Carcinoma Trial in Boston (Supervised Circuit Training)

Not yet recruiting
  • PROSTATE CANCER
  • +2 more
  • Supervised Circuit Training
  • Boston, Massachusetts
  • +2 more
Sep 13, 2023

Metastatic Hormone Sensitive Prostate Cancer Trial in China (Enzalutamide, Placebo, Androgen deprivation therapy (ADT))

Active, not recruiting
  • Metastatic Hormone Sensitive Prostate Cancer
  • Beijing, China
  • +29 more
Jan 7, 2023

Treatment Trial in Shanghai (ADT, SBRT)

Recruiting
  • Treatment
  • ADT
  • SBRT
  • Shanghai, Shanghai, China
    Changhai hospital
Aug 9, 2022

Prostate Cancer Trial in Multiple Locations (Darolutamide 600 mg twice daily, Placebo 600 mg twice daily, Androgen deprivation

Recruiting
  • Prostate Cancer
  • Darolutamide 600 mg twice daily
  • +2 more
  • Multiple Locations, China
    Many Locations
Aug 2, 2022

Prostate Cancer Trial in Durham (drug, radiation, procedure)

Not yet recruiting
  • Prostate Cancer
  • Durham, North Carolina
    Duke University Medical Center
Aug 16, 2022

Prostate Cancer, Insulin Resistance, Diabetes, Type 2 Trial in Buffalo (Pioglitazone 30 mg, Placebo)

Recruiting
  • Prostate Cancer
  • +3 more
  • Pioglitazone 30 mg
  • Placebo
  • Buffalo, New York
    Diabetes and Endocrinology Research Center of WNY
Oct 26, 2022

Prostate Cancer, Biochemical Recurrence, High Risk Trial in Nanjing, Nantong (Apalutamide 60mg Tab, Androgen deprivation

Not yet recruiting
  • Prostate Cancer
  • +2 more
  • Apalutamide 60mg Tab
  • Androgen deprivation therapy(ADT)
  • Nanjing, Jiangsu, China
  • +2 more
Mar 17, 2023

Metastatic Prostate Cancer, Castration-Sensitive Prostate Cancer Trial in Shanghai (drug, procedure, radiation)

Not yet recruiting
  • Metastatic Prostate Cancer
  • Castration-Sensitive Prostate Cancer
  • Shanghai, Shanghai, China
  • +1 more
Feb 4, 2023

Advanced Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Carcinoma Trial in Duarte (procedure, drug, other)

Not yet recruiting
  • Advanced Prostate Carcinoma
  • +4 more
  • Bright White Light Therapy
  • +4 more
  • Duarte, California
    City of Hope Medical Center
May 8, 2023

Localized Prostate Carcinoma, Prostate Adenocarcinoma Trial in Seattle (Best Practice, Dietary Intervention, Exercise

Recruiting
  • Localized Prostate Carcinoma
  • Prostate Adenocarcinoma
  • Best Practice
  • +4 more
  • Seattle, Washington
  • +1 more
Jan 9, 2023

Metastatic Castration-resistant Prostate Cancer Trial in New Orleans (Avelumab, 2nd generation ADT (abiraterone or

Terminated
Has Results
  • Metastatic Castration-resistant Prostate Cancer
  • Avelumab
  • 2nd generation ADT (abiraterone or enzalutamide)
  • New Orleans, Louisiana
    Tulane University School of Medicine
Apr 6, 2022

Prostate Cancer Trial (PSMA-radioguided surgery, ADT)

Not yet recruiting
  • Prostate Cancer
  • PSMA-radioguided surgery
  • ADT
  • (no location specified)
Sep 22, 2022

Prostate Cancer Trial (ADT, Enzalutamide, Talazoparib)

Not yet recruiting
  • Prostate Cancer
  • ADT
  • +4 more
  • (no location specified)
May 15, 2023

Learn More About How Safe Darolutamide is Under Real-world

Not yet recruiting
  • Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
  • No Intervention
  • Multiple Locations, Japan
    Many Locations
Aug 24, 2023